← Back to Clinical Trials
Recruiting NCT06757829

NCT06757829 Pulmonary Functions in Sickle Cell Disease: Response to Acu-TENS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06757829
Status Recruiting
Phase
Sponsor Cairo University
Condition Sickle Cell Disease
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-12-15
Primary Completion 2025-05-01

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
inspiratory muscle training and acupucnture like transcutanoeus electrical nerve stimulationinspiratory muscle training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-12-15 with a primary completion date of 2025-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

pulmonary complications are common in sickle cell disease patients. Respiratory training using inspiratory muscle trainer (IMT) is usually a good choice to improve these complications. Recently, acupuncture like transcutaneous electrical nerve stimulation (AC-tens) may also improve these complications.

Eligibility Criteria

Inclusion Criteria: * sickle cell disease patients * non obese patients Exclusion Criteria: * patients with any systemic or chest or renal or hepatic or neurological diseases * women with lactation or pregnancy * patients atacks of vasoocclusive crisis

Contact & Investigator

Central Contact

Ali Isamil, Lecturer

✉ ali.mohamed@pt.cu.edu.eg

📞 0201005154209

Principal Investigator

Ali Ismail, lecturer

PRINCIPAL INVESTIGATOR

Cairo University

Frequently Asked Questions

Who can join the NCT06757829 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06757829 currently recruiting?

Yes, NCT06757829 is actively recruiting participants. Contact the research team at ali.mohamed@pt.cu.edu.eg for enrollment information.

Where is the NCT06757829 trial being conducted?

This trial is being conducted at Dokki, Egypt.

Who is sponsoring the NCT06757829 clinical trial?

NCT06757829 is sponsored by Cairo University. The principal investigator is Ali Ismail, lecturer at Cairo University. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology